London, June 20, 2026, 16:03 (BST)
- GSK ended Friday at 1,925.5 pence, inching up 0.1% for the session, though shares slipped about 3% over the week. The FTSE 100 fell 1%.
- Utebzi got the green light from the U.S. as the first oral carbapenem antibiotic for some adults with complicated urinary tract infections.
- GSK isn’t set to hold an investor event next week. The company will post its Q2 results and give a portfolio update on July 28.
GSK closed Friday at 1,925.5 pence, up 0.13% on the day but down 2.95% for the week. The stock lagged the FTSE 100 by about two percentage points over the week.
Shares fell after the pipeline win. Investors look to be focusing less on regulatory progress and more on when GSK can launch, how products will sell, and how much its recent acquisitions cost. The approval gives a boost to GSK’s infectious-disease business, but there’s no big sales pop yet.
FDA clears Utebzi for tough urinary tract infections in adults The U.S. FDA has okayed Utebzi, or tebipenem pivoxil, to treat complicated urinary tract infections, even kidney infections, for adults who don’t have many oral options. Amanda Peppercorn, who runs the program at GSK, said the drug is aimed at “serving the patients within the carbapenem footprint with an oral option.” GSK is planning to launch in the U.S. by the end of 2026. Reuters
Traders are watching GSK after it agreed to buy Nuvalent for $10.6 billion, the biggest deal for the company in over ten years. CEO Luke Miels said the company is buying “essentially three products in one.” Bank of America called the move “bold” and said it brings in two “imminent growth drivers.” The lung-cancer drugs take GSK deeper into a fight with AstraZeneca, but it will have to go up against Pfizer and Roche, who already have products in that market. Reuters
UK stocks dropped Thursday as the Bank of England kept rates at 3.75%. Worries about inflation and political risk also pressured the market. GSK, known for its defensive edge, still lost ground.
GSK’s operating base is holding up. First-quarter sales climbed 5% at constant rates to £7.6 billion, helped by a 14% jump in specialty medicines. The company kept its 2026 guidance for 3% to 5% sales growth and 7% to 9% core EPS growth, sticking to its goal of topping £40 billion annual sales by 2031.
Still, some investors are raising doubts about the strength of the recent earnings run. After the first quarter, James Eugene at Verso Investment Management flagged “quality concerns around the earnings beat,” pointing to “one-off factors.” The July numbers now have to prove specialty-medicine demand can make up for weaker sales in older general medicines. Reuters
But GSK is taking on some risk with the Nuvalent deal. The company says the move will dilute core earnings per share by a low-single-digit percentage in 2026, 2027 and 2028, turning accretive in 2029. Debt will increase. The bet is on fast approvals and successful launches for late-stage cancer drugs.
No scheduled catalyst from the company is on tap for next week. GSK isn’t due for an official update until its second-quarter results and portfolio presentation on July 28. Shares could be more sensitive in the interim to sector moves, broad market swings, or any new regulatory or deal headlines.
